ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ACRS Aclaris Therapeutics Inc

1.81
0.01 (0.56%)
After Hours
Last Updated: 22:28:30
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aclaris Therapeutics Inc NASDAQ:ACRS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.01 0.56% 1.81 1.80 1.84 1.935 1.80 1.82 717,931 22:28:30

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

30/04/2024 12:00pm

GlobeNewswire Inc.


Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart


From Oct 2023 to Oct 2024

Click Here for more Aclaris Therapeutics Charts.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets.

Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcast live over the internet and can be accessed by logging into the “Investors” page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Therapeutics Contact:

investors@aclaristx.com

1 Year Aclaris Therapeutics Chart

1 Year Aclaris Therapeutics Chart

1 Month Aclaris Therapeutics Chart

1 Month Aclaris Therapeutics Chart